These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32727497)

  • 1. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
    Huang J; Gu F; Ji T; Zhao J; Li G
    Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
    Wan J; Liu K; Li K; Li G; Zhang Z
    Radiat Oncol; 2015 Aug; 10():162. PubMed ID: 26238572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.
    Klopp AH; Moughan J; Portelance L; Miller BE; Salehpour MR; Hildebrandt E; Nuanjing J; D'Souza D; Souhami L; Small W; Gaur R; Jhingran A
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):83-90. PubMed ID: 23582248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
    Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
    Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
    Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin.
    Lewis S; Chopra S; Naga P; Pant S; Dandpani E; Bharadwaj N; Mahantshetty U; Engineer R; Swamidas J; Ghosh J; Gupta S; Shrivastava S
    Br J Radiol; 2018 Dec; 91(1092):20180005. PubMed ID: 30179056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
    Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
    Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.
    Chang Y; Yang ZY; Li GL; Li Q; Yang Q; Fan JQ; Zhao YC; Song YQ; Wu G
    Int J Gynecol Cancer; 2016 May; 26(4):770-6. PubMed ID: 26844613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).
    Mell LK; Sirák I; Wei L; Tarnawski R; Mahantshetty U; Yashar CM; McHale MT; Xu R; Honerkamp-Smith G; Carmona R; Wright M; Williamson CW; Kasaová L; Li N; Kry S; Michalski J; Bosch W; Straube W; Schwarz J; Lowenstein J; Jiang SB; Saenz CC; Plaxe S; Einck J; Khorprasert C; Koonings P; Harrison T; Shi M; Mundt AJ;
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):536-545. PubMed ID: 28126303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.
    Mell LK; Tiryaki H; Ahn KH; Mundt AJ; Roeske JC; Aydogan B
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1504-10. PubMed ID: 18640499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical study of acute toxicity of pelvic bone marrow-sparing intensity-modulated radiotherapy for cervical cancer.
    Sun S; Chen Z; Li P; Wu J; Zhu B; Zhang X; Wu C; Lin R; Zhou Y; Chen W
    Ginekol Pol; 2023; 94(2):101-106. PubMed ID: 35156692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-photon emission computed tomography-defined active bone marrow-sparing volumetric-modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single-center prospective randomized controlled trial.
    Wang S; Liu J; Lei K; Jia Y; Wang C; Zhang X; Li T
    Cancer; 2023 Jul; 129(13):1995-2003. PubMed ID: 37043337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Analysis of VMAT and IMRT Techniques: Evaluation of Dose Constraints and Bone Marrow Sparing in Cervical Cancer Patients Undergoing Chemoradiotherapy.
    Thakur N; Kaur H; Kaur S; Lehal P; Sudan M; Jain N; Sharma R; Sharma A
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):139-144. PubMed ID: 38285777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study.
    Li W; Ma L; Li F; Li K; Zhang Y; Ren H; Bao X; Guo Y; Guo Y; Wang M; Li D; Duan Y; Ma X; Wang Z; Wang Y; Yin R
    Radiat Oncol; 2024 Apr; 19(1):46. PubMed ID: 38594678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.
    Erpolat OP; Alco G; Caglar HB; Igdem S; Saran A; Dagoglu N; Aslay I; Ozsaran Z; Demirci S; Keven E; Guney Y; Akmansu M; Kilic D; Bayman E; Etiz D; Mandel NM
    Eur J Gynaecol Oncol; 2014; 35(1):62-6. PubMed ID: 24654465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
    Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
    Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.
    Chen H; Zhong Q; Liu Y; Li J; Deng W; Wang J; Zhou S; Yu Z; Huang X; Huang Y; Zhen B; Wei J; Zhang W; Ruan X; Xiao L
    Radiat Oncol; 2023 Nov; 18(1):193. PubMed ID: 38012675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
    Bazan JG; Luxton G; Mok EC; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):700-6. PubMed ID: 22414279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.